Healthcare Industry News: CoFactor
News Release - July 6, 2007
Dade Behring Introduces Innovance(TM) D-DIMER TestTest excludes presence of deep vein thrombosis and pulmonary embolism and is available on a wide range of automated coagulation systems
DEERFIELD, Ill.--(HSMN NewsFeed)--Today at the International Society on Thrombosis and Haemostasis (ISTH) in Geneva, Switzerland, Dade Behring Inc. (NASDAQ:DADE ), the world's largest company solely dedicated to clinical diagnostics, introduced a next-generation D-dimer coagulation test, Innovance(TM) D-DIMER, in Europe, Canada, and the Middle East and Asia Pacific regions. The Company also anticipates introducing a similar test in the United States in the future.
The Innovance(TM) D-DIMER test has a validated sensitivity for exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE), conditions associated with blood clots in the human circulatory system. The test benefits clinical laboratories of all types and sizes because it is a fully automated test that can be run on multiple coagulation systems offered through Dade Behring.
"By using a simple blood test to help diagnose a patient with a possible blood clot, physicians are able to more quickly initiate proper treatment," said Jim Reid-Anderson, Chairman, President and CEO, Dade Behring. "One of Dade Behring's priorities is to develop new tests such as this one, which assist health care providers around the world in offering differentiated care to their patients."
DVT and PE are serious medical conditions, affecting millions of people worldwide every year. DVT is caused by the formation of a blood clot in the deep veins of the legs, pelvis or upper extremities, leading to either partially or completely blocked circulation. PE occurs when a clot breaks loose and travels to pulmonary arteries. Both conditions could cause death if they are not diagnosed and treated properly.
Studies have shown that measurement of D-dimer may also be valuable in the evaluation of rethrombosis risk, to monitor potential coagulation disorders in pregnancy, and as an aid in the diagnosis of disseminated intravascular coagulation (DIC). Dade Behring continues to evaluate Innovance(TM) D-DIMER for these potential clinical indications.
About Dade Behring Hemostasis (coagulation and platelet function testing)
With more than 30 years of experience, Dade Behring is the largest provider of hemostasis analyzers and tests in the world. Under its own name and through a global alliance with Sysmex Corporation, Dade Behring offers a wide selection of analyzers to meet the needs of low-, medium-, and high-volume laboratories, including high-speed analyzers and cap piercing capability to improve operational efficiencies in the laboratory. The Company also offers an option to connect the high-volume Sysmex® CA-7000 Coagulation Analyzer to the StreamLAB® Workcell-- Dade Behring's scalable automation solution.
The Innovance(TM) brand name represents the company's commitment to the ongoing advancement and development of innovative coagulation assays to assess bleeding and thrombotic risk and disorders. Dade Behring has many "firsts" in the coagulation industry including pioneering the first recombinant tissue factor, Innovin®, which is used in the routine prothrombin time (PT) coagulation test. The company also developed the first automated ristocetin CoFactor activity test that detects Von Willebrand disease, which is the most common inherited bleeding disorder. Dade Behring also has a leading position in automated platelet function analysis.
About Dade Behring
With 2006 revenue of more than $1.7 billion, Dade Behring is the world's largest company solely dedicated to clinical diagnostics. It offers a wide range of products, systems and services designed to meet the day-to-day needs of clinical laboratories, delivering innovative solutions to customers and enhancing the quality of life for patients. Additional company information is available on the Internet at www.dadebehring.com.
This press release may contain "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward statements include information regarding the intent, belief or current expectation of the company and members of its senior management team, including, without limitation, expectations regarding prospective performance and opportunities and the outlook for the company's businesses, performance, opportunities and regulatory approval. In addition, the company is in the process of a major new product launch, which involves risks and uncertainties regarding product performance, costs of introduction and support, and customer acceptance. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by the company.
Source: Dade Behring
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.